
Renal Cell Carcinoma
Latest News
Latest Videos

More News



The treatment combination of the tyrosine kinase inhibitor axitinib plus pembrolizumab was tolerable in 52 patients with treatment-naïve advanced renal cell carcinoma, and the combination demonstrated promising antitumor activity, according to the lead researcher from Georgetown Lombardi Comprehensive Cancer Center in Washington, DC.

Patients who have intermediate or poor-risk advanced renal cell carcinoma may see extended progression-free survival and overall survival in a phase II trial comparing pazopanib with temsirolimus, according to a presentation by Nizar M. Tannir, MD, FACP, at the 2018 Genitourinary Cancers Symposium.







Therapeutic Approach for Metastatic Renal Cell Carcinoma








Intermediate-Risk Newly Diagnosed Metastatic Renal Cell Carcinoma

The phase III ADAPT trial investigating rocapuldencel-T in patients with metastatic renal cell carcinoma has been stopped by Argos Therapeutics after findings of an interim analysis revealed the immunotherapy was unlikely to meet any of the primary endpoints.

Neeraj Agarwal, MD, recently discussed the treatment considerations and decisions he makes when treating patients with renal cell carcinoma. Agarwal, director of the Genitourinary Oncology Program, University of Utah School of Medicine, explained his treatment decisions based on a case scenario during a <em>Targeted Oncology </em>live case-based peer perspectives presentation.

Based on data from the phase III CheckMate-214 trial, the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) has been approved by the FDA as a frontline treatment for intermediate- and poor-risk patients with advanced renal cell carcinoma.

Martin H. Voss, MD, an assistant attending at Memorial Sloan Kettering Cancer Center, discusses recent data supporting the use of neoadjuvant therapy in patients with locally advanced kidney cancer.

According to findings from the phase III ATLAS trial, disease-free survival was not extended with adjuvant axitinib (Inlyta) versus placebo for patients at high risk of recurrent renal cell carcinoma after nephrectomy.

Ani S. Balmanoukian, MD, discusses immunotherapy developments in GU malignancies




















































